Evaluation of Differences Between the Standered NAC Regimen Protocol and the SNAP Regimen Protocol in the Treatment of Paracetamol Toxicity for Cases Presented Early and Late to Assiut University Hospitals in Terms of Safety and Efficiecy.
Condition(s) studied
Investigational drug(s) / intervention(s)
Evidence-based medical care for paracetamol toxicity: adminstration of Standered 21 h NAC regimen for patient comes early within 8 h from ingestion of toxic dose of paracetamol
Evidence-based medical care for paracetamol toxicity: adminstration of Standered 21 h NAC regimen for patient comes late after 8 h from ingestion of toxic dose of paracetamol
Evidence-based medical care for paracetamol toxicity: adminstration of 12 h NAC regimen for patient comes early within 8 h from ingestion of toxic dose of paracetamol
Evidence-based medical care for paracetamol toxicity: adminstration of 12 h NAC regimen for patient comes late after 8 h from ingestion of toxic dose of paracetamol
Study summary
Evaluation of differences between the 21 h NAC regimen protocol and the 12 h NAC regimen protocol in the treatment of paracetamol toxicity (over dose) for cases presented early and late to Assiut University Hospitals in terms of safety and efficiecy.
Eligibility
Primary outcome measure(s)
- 1-Change in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — 1- Day 2
1-Mean change in ALT and AST levels (IU/L) from baseline to end of treatment - change in serum creatinine level — Day 2
Mean change in serum creatinine (mg/dL) from baseline to end of treatment. - Incidence of adverse drug reactions — Day 2
Number of participants who develop adverse drug reactions including nausea, vomiting, or anaphylactoid reactions during treatment
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Faculty of Medicine Assiut University | Asyut | Egypt |
More Assiut University trials in Egypt
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07454590 on ClinicalTrials.gov ↗ ← All trials in Egypt